Multiple Myeloma

expert roundtables

by James R. Berenson, MD, Carol Ann Huff, MD, Paul G. Richardson, MD

Several novel therapies have been approved by the US Food and Drug Administration for relapsed/refractory multiple myeloma, including the immunomod......READ MORE

clinical topic updates

by Carol Ann Huff, MD

Use of triplet combination therapy in multiple myeloma—particularly the immunomodulatory drug (IMiD)–proteasome inhibitor (PI) triplets—relates to ......READ MORE

patient care perspectives

by James R. Berenson, MD

Owing to significant bone pain, vulnerability to infection, fatigue, and other symptomatology related—and unrelated—to multiple myeloma, the diseas......READ MORE

clinical topic updates

by James R. Berenson, MD

While most patients with multiple myeloma will achieve disease control with autologous stem cell transplant (ASCT), virtually all of these individu......READ MORE